PreveCeutical Medical Valuation

Is PREV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PREV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PREV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PREV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PREV?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PREV. This is calculated by dividing PREV's market cap by their current preferred multiple.
What is PREV's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$13.38m

PREV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-21x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does PREV's PB Ratio compare to its peers?

The above table shows the PB ratio for PREV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.9x
TILT TILT Holdings	0.2x	45.2%	CA$17.4m
RVV Revive Therapeutics	1.1x	n/a	CA$10.5m
XTRX Adastra Holdings	0.7x	n/a	CA$12.3m
XRTX XORTX Therapeutics	1.6x	120.0%	CA$10.1m
PREV PreveCeutical Medical	n/a	n/a	CA$13.4m

Price-To-Book vs Peers: PREV has negative equity and a Price-To-Book Ratio (-3x) compared to the peer average (0.9x).

Price to Earnings Ratio vs Industry

How does PREV's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	57.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	57.1%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: PREV has negative equity and a Price-To-Book Ratio (-3x) compared to the Canadian Pharmaceuticals industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is PREV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PREV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PREV's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.